IP Law Group Gives Fed. Circ. Input In Ariad Case

Law360, New York (October 19, 2009, 5:13 PM EDT) -- The New York Intellectual Property Law Association has filed an amicus brief in the appeal of the Ariad Pharmaceuticals Inc. patent suit — which could make patents easier to prosecute and tougher to invalidate — saying the court should look to the enablement requirement to settle the case.

NYIPLA filed the brief on Thursday with the U.S. Court of Appeals for the Federal Circuit, which is holding an en banc hearing of the suit.

The case, an infringement suit over osteoporosis drug Evista and septic shock...
To view the full article, register now.